OBJECTIVE： To observe the clinical efficacy and safety of  Fuyankang combined with azithromycin in the treatment of pelvic inflammatory disease. METHODS： 90 patients with pelvic inflammatory disease were selected and randomly divided into observation group and control group， with 45 cases in each group. Control group was given Lactose acid azithromycin for injection 500 mg， ivgtt， qd， and then Azithromycin capsule 250 mg， po， qd； observation group was additionally given Fuyankang Tablet 1.56 g， tid， on the basis of control group. A treatment course of 2 groups lasted for 7 d， and both received 3 courses of treatment. Clinical efficacies of 2 groups were observed as well as the level of CRP， IL-2 and life quality score before and after treatment， and the occurrence of ADR was compared between 2 groups. RESULTS： Total effective rate of observation group was 97.78％， which was significantly higher than that of control group （86.67％）， with statistical significance  （P＜0.05）.  The level of CRP， IL-2 and life quality score of 2 groups were improved significantly after treatment， and the observation group was more better than the control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Fuyankang combined with Azithromycin is effective for pelvic inflammatory disease， and can improve the quality of life， reduce inflammation cytokines infiltration and the generation of inflammatory medium with good safety.